Lancet HIV

Papers
(The H4-Index of Lancet HIV is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Transplant donation without discrimination199
How do we prevent anal cancer in people living with HIV?192
Lung cancer in people living with HIV156
Argentina updates HIV laws133
Evidence supports use of on-demand PrEP for HIV prevention128
How much could long-acting PrEP cost in South Africa?126
The Australian AIDS crisis through the eyes of volunteers125
Are we ready for long-acting HIV treatment for adolescents?122
Correction to Lancet HIV 2022; 9: e791–800120
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia 108
Lenacapavir: an attractive option, but proceed with caution107
The time to end the war on drugs is long overdue94
Risk estimation in HIV reveals our usual blind spots91
Steps toward quick and equitable roll-out of lenacapavir87
Optimising anal cancer screening through risk stratification86
HIV and COVID-19: juxtaposition of two pandemics84
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial80
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c77
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?77
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial76
Controversial chronicler of LGBTQ rights68
Redefining care: injectable HIV treatment for adolescents63
All roads lead to Westminster: the infected blood scandal62
Unheard testimony57
Fate of people with HIV in jeopardy in Ukraine55
Gains and gaps: addressing HIV in diverse sex worker groups55
Stigma reduction is key to improving the HIV care continuum52
Game-changing study of second-line HIV treatment51
Integration of sexual health and HIV services50
A public health approach to drug use crucial to ending AIDS50
Recent gay Black history in the UK49
Reducing HIV transmission in British Columbia, Canada49
Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study47
More evidence for worse COVID-19 outcomes in people with HIV46
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther45
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study44
Equitable access to long-acting PrEP on the way?43
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis43
Need for transgender-specific data from Asia43
Sex as a biological variable in HIV-1 and schistosome co-infection41
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries41
0.33948683738708